Drugs Like Ozempic Linked to Lower Cancer Risk in Study (1)

Blockbuster weight loss and diabetes drugs may lower patients’ risk of developing some common types of cancer that are closely linked to obesity, new evidence suggests.

Patients with Type 2 diabetes who were prescribed drugs known as glucagon-like peptide-1, or GLP-1, developed fewer obesity-related cancers than patients who were treated with insulin, according to a study published Friday in JAMA Network Open. But the newer drugs didn’t perform better than metformin, an older diabetes drug with known cancer risk reduction properties.

The group of drugs the study looked at includes Novo Nordisk A/S’s Ozempic, a diabetes treatment. Since the ...